Infections in lung transplanted patients: A review

Pulmonology. 2024 May-Jun;30(3):287-304. doi: 10.1016/j.pulmoe.2022.04.010. Epub 2022 Jun 14.

Abstract

Lung transplantation can improve the survival of patients with severe chronic pulmonary disorders. However, the short- and long-term risk of infections can increase morbidity and mortality rates. A non-systematic review was performed to provide the most updated information on pathogen, host, and environment-related factors associated with the occurrence of bacterial, fungal, and viral infections as well as the most appropriate therapeutic options. Bacterial infections account for about 50% of all infectious diseases in lung transplanted patients, while viruses represent the second cause of infection accounting for one third of all infections. Almost 10% of patients develop invasive fungal infections during the first year after lung transplant. Pre-transplantation comorbidities, disruption of physical barriers during the surgery, and exposure to nosocomial pathogens during the hospital stay are directly associated with the occurrence of life-threatening infections. Empiric antimicrobial treatment after the assessment of individual risk factors, local epidemiology of drug-resistant pathogens and possible drug-drug interactions can improve the clinical outcomes.

Keywords: Bacteria; Fungi; Infections; Lungs; Transplant; Viruses.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Bacterial Infections / epidemiology
  • Cross Infection / epidemiology
  • Humans
  • Lung Transplantation* / adverse effects
  • Postoperative Complications / epidemiology
  • Postoperative Complications / microbiology
  • Risk Factors
  • Virus Diseases / epidemiology
  • Virus Diseases / etiology